Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300950 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
A Phase 2 study of Pancreas Cancer, sponsored by GlobeImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT00300950: Completed Phase 2 study of Pancreas Cancer, sponsored by GlobeImmune.
NCT00300950 is a Phase 2 study of Pancreas Cancer that has completed, run by GlobeImmune. The registered enrollment target is 176 participants, below the 904-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00300950, a Phase 2 study of Pancreas Cancer, has completed, sponsored by GlobeImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients. Patients will be monitored for recurrence as well as safety, and immune responses related to the injections.
Conditions Studied
Interventions
- DRUG Gemcitabine
- BIOLOGICAL GI-4000
Study Locations (20)
Texas
- Texas Oncology, PA - Dallas
- The Texas Cancer Center Dallas Southwest - Dallas
- Baylor College of Medicine - Houston
- South Texas Oncology & Hematology - San Antonio
- Tyler Cancer Center - Tyler
California
- Tower Cancer Research Foundation - Beverly Hills
- University of California San Diego - La Jolla
- UCLA Medical Center - Los Angeles
Tamil Nadu
- PSG Hospitals - Peelamedu, Coimbatore
- Sri Ramchandra Medical College & Research Institute - Ponur, Chennai
Alabama
- University of Alabama at Birmingham - Birmingham
District of Columbia
- Georgetown University Medical Center / Lombardi Cancer Center - Washington D.C.
Illinois
- Rush University Medical School - Chicago
Minnesota
- Minnesota Oncology Hematology, PA - Minneapolis
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2006-01 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
What the finished NCT00300950 record still lists
NCT00300950 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 904-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Pancreas Cancer appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00300950 names 20 study sites across 13 states, led by Texas, California, Tamil Nadu.
Frequently Asked Questions
What is clinical trial NCT00300950 about?
NCT00300950 is a clinical study titled "Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer". The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients. Patients will be monitored for recurrence as well as safety, and immune responses related to the injections.
What is the current status of trial NCT00300950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2006-01. Estimated completion is 2015-02.
What conditions does trial NCT00300950 study?
This clinical trial studies the following conditions: Pancreas Cancer.
What interventions are being tested in trial NCT00300950?
The interventions under investigation include: Gemcitabine (DRUG), GI-4000 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00300950?
This trial is sponsored by GlobeImmune, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00300950 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00300950's enrollment target sits among peer trials
176 18th of 54 higher than 37 of 54 other Pancreas Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
-
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
ACTIVE NOT RECRUITING · Phase 2
-
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia